Ultragenyx stock jumps after FDA approves Fayuvi for Sanfilippo A
FDA approval of Ultragenyx Pharmaceutical’s Fayuvi for children with Sanfilippo syndrome type A sent the shares up about 12% to $14.44 late Thursday.
Shares of Ultragenyx Pharmaceutical climbed after the Food and Drug Administration said it approved the company's Fayuvi for children with Sanfilippo syndrome type A. 44, late Thursday, but has fallen 37% for the year. The agency said this is the first ap…